Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) saw strong trading volume on Tuesday after Guggenheim raised their price target on the stock from $9.00 to $13.00. Guggenheim currently has a buy rating on the stock. 123,661 shares traded hands during mid-day trading, an increase of 471% from the previous session's volume of 21,653 shares.The stock last traded at $5.35 and had previously closed at $6.19.
Separately, Piper Sandler initiated coverage on shares of Inventiva in a research note on Wednesday, August 27th. They issued an "overweight" rating and a $26.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Inventiva has an average rating of "Moderate Buy" and a consensus price target of $14.83.
Get Our Latest Research Report on IVA
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC purchased a new position in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.
Inventiva Price Performance
The firm's 50 day moving average price is $3.90 and its two-hundred day moving average price is $3.46.
Inventiva Company Profile
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Recommended Stories
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
